Qingyun Tech Secures Tens of Millions in Series C Funding to Lead Digital Marketing Innovation for Pharma Companies

VCBeat has learned that the leading enterprise in the digital marketing sectorShanghai Qingyun Medical Technology Co., Ltd. (hereinafter referred to as "Qingyun Tech")Recently Announced CompletionTens of millions of dollars's new round of financing, led byBayland CapitalLead Investor, Existing ShareholdersLong Hill CapitalCo-investment,Life CapitalServing as the financial advisor. The funds from this round will further accelerate the application upgrades and functional innovations of Qingyun Technology’s self-developed AI-driven digital marketing platform, while enhancing its omni-channel marketing network layout focused on county-level primary markets. By providing high-quality and efficient marketing data, tools, and services, the company aims to comprehensively support pharmaceutical enterprises in advancing their digital marketing development and conversion.

Qingyun Technology was established in 2017 and is aAI-Powered Digital Marketing Platform Enterprise Focused on the Pharmaceutical Industry。

As one of the earliest innovative technology companies in China to deploy virtual representatives, Qingyun Technology offers a comprehensive multi-channel digital marketing solution. Leveraging deep, multi-dimensional insights into healthcare institutions and physicians, and empowered by artificial intelligence and deep machine learning, the solution precisely delivers high-value, highly relevant medical knowledge. Beyond providing precise academic content, Qingyun Technology’s virtual representatives deliver services to physicians at optimal times and within extremely granular scenarios. Through close interactions, the platform fosters continuous, positive communication between pharmaceutical companies and physicians. Physician feedback, in turn, drives the iteration of technology and services, enabling rapid responses to the evolving pharmaceutical landscape and clinical needs. This approach constructs an “ecological closed-loop” marketing solution that is real-time, intelligent, and platform-based, catering to diverse application scenarios.

Since 2021, Qingyun Technology has been building an omnichannel digital marketing network in county-level markets, based on its existing multi-channel marketing business, to directly deliver sales results for pharmaceutical companies. Currently, Qingyun Technology’s omnichannel marketing team has covered the entire country.20 unitsProvincial Exceeds700 unitsdistricts and counties. By integrating online virtual representatives with offline pharmaceutical sales representatives, we truly achieve a closed-loop pharmaceutical marketing model characterized by extensive coverage, high efficiency, and personalization. Meanwhile, Qingyun Technology’s proprietary private-domain platform includesZhiyun Medical Path, Zhiyun Xiaoyou, Zhiyun Communityand other products cover nearly600,000Primary care physicians: To expand brand reach for pharmaceutical companies and enhance physician engagement experiences, a variety of solutions have been introduced.

Qingyun’s core team comprises senior executives from leading domestic CSO firms, commercial distribution enterprises in China, and digital marketing divisions of multinational pharmaceutical companies. It is a professional management team with in-depth understanding of pharmaceutical companies’ needs, the evolution of the Chinese pharmaceutical market, policy trends, and industry risks. Since 2021, the company has collaborated with nearly 40 domestic and international pharmaceutical enterprises, covering therapeutic areas including cardiovascular, respiratory, vaccines, urology, and oncology, with an annual business growth rate exceeding150%，Team SizeNearly 800 people.

As a key driver for cost reduction, efficiency improvement, and business innovation, digital marketing is poised to unlock a broader market, influenced by factors such as regulatory standardization and pharmaceutical company reforms. According to the “2022 Report on the Digital Marketing Industry in Pharmaceuticals” by VCBeat, the pharmaceutical digital marketing sector has entered a golden growth phase, with the market size expected to reach RMB 40.3 billion in 2022.

Precision digital marketing, driven by technology and guided by data-driven decision-making, will break through temporal and spatial constraints, fully demonstrating advantages such as convenience, personalization, and targeted promotion. Digital marketing has become an unstoppable trend and is bound to become the new normal in pharmaceutical marketing.

Yan Guowei, Founder of Qingyun Technologystated: “We extend our sincere gratitude to all investment institutions for their support and recognition of Qingyun Technology. Over the past five years, Qingyun Technology has deeply cultivated the grassroots market, committing itself to empowering clinical physicians, enhancing pharmaceutical marketing efficiency, and delivering high-quality medicines to patients through a new type of digital marketing platform driven by technology and data-based decision-making. It can be said that our increasingly sophisticated digital marketing system and the extensive accumulation of physician behavioral data constitute the core competitiveness driving Qingyun Technology’s sustained development. In particular, over the past two years, our marketing collaborations with leading multinational pharmaceutical companies such as AstraZeneca and Merck KGaA (Germany) on multiple products in county-level markets have fully validated the effectiveness and sustainability of the omnichannel marketing model established by Qingyun Technology. Driven by policy developments in China’s pharmaceutical market and the trend toward marketing upgrades among pharmaceutical enterprises, digital marketing is inevitably demonstrating its characteristics of high efficiency, precision, and compliance, thereby becoming the new normal in pharmaceutical marketing. Looking ahead, Qingyun Technology will comprehensively upgrade its digital marketing service offerings for pharmaceutical companies, covering multiple aspects including the provision of marketing data capabilities, the integration of marketing tools, and the assurance of marketing outcome delivery, thereby fully meeting the needs of pharmaceutical enterprises for in-depth development of digital marketing. While empowering physicians to enhance their clinical academic capabilities, we aim to ensure that more high-quality pharmaceutical products benefit patients across China.”

Dai Yiren, Partner at Bayland Capitalstated: “Cost-control measures, such as centralized volume-based procurement and national reimbursement drug price negotiations, are continuously squeezing the profit margins of pharmaceutical companies. As a result, digital marketing models that emphasize cost reduction, efficiency enhancement, compliance, and traceability have become a major trend in the industry. Qingyun Technology possesses dual expertise in pharmaceutical marketing and data technology. By leveraging technological solutions, it has developed an integrated online-and-offline academic promotion model, enabling pharmaceutical companies to connect with a broader physician community more precisely and at lower costs. As domestic innovative biopharmaceutical companies continue to advance their pipelines, Qingyun Technology will also support Chinese biotech firms in transitioning from early-stage R&D to commercialization, becoming a key component in helping them achieve a complete commercialization loop. Bayland Capital is honored to participate in this financing round. We look forward to working closely with Qingyun Technology to facilitate the commercialization of high-quality pharmaceutical products and ultimately benefit patients.””

Jiang Xiaodong, Managing Partner at Long Hill Capitalstated: “Amid the overarching themes of healthcare reform, such as strengthening primary care and pharmaceutical reforms, Qingyun Technology, under the leadership of Mr. Yan, has actively explored new pathways for digital pharmaceutical marketing tailored to China’s primary care market, providing a successful model. Particularly during the pandemic, the ‘Qingyun Model’ further demonstrated its capability to deeply reach and efficiently serve the primary healthcare system. As the Series A investor in Qingyun, Long Hill Capital remains firmly confident that the ‘Qingyun Model’ will continue to add value for pharmaceutical companies, empower physicians, and ultimately achieve clinical benefits for patients at the primary care level.”

Bayland Capital, established in 2019, leverages the industrial background of Pharmaron (Stock Codes: 300759.SZ/3759.HK) to focus on equity investments in the biopharmaceutical sector. By applying a unique industry perspective and drawing on extensive experience in industry, scientific research, management, and capital markets, the Bayland Capital team conducts global investments with a particular focus on globally leading biopharmaceutical R&D services and technology innovation platforms, biotechnology companies, and medical device companies. Bayland Capital is committed to becoming a trusted long-term partner and a vital link between life sciences, the health industry, and capital.

Long Hill Capital is a new generation of theme-driven venture capital funds. In the fields of big health and aging, Long Hill Capital is committed to investing in technology-driven business model innovations, making longevity a gift of life to everyone in China's rapidly aging society. Long Hill Capital has offices in Shanghai and Beijing, with a total fund size under management reaching 6 billion yuan. Its investors include top-tier institutions such as endowment funds from globally renowned universities and hospitals, foundations, pension funds, and leading fund-of-funds. Long Hill Capital is dedicated to continuously creating value for the growth and development of companies in emerging sectors.

Life Capital is committed to its mission of “Empowering Leaders in the Healthcare Industry.” As a leading financial services institution in China focused on the broader healthcare sector, it offers investment banking and venture capital services. Its team comprises professionals from renowned investment banks, academic institutions, and healthcare enterprises, bringing decades of accumulated expertise in the medical and investment/financing fields. In recent years, the team has completed dozens of financing and M&A transactions in the healthcare industry, with a cumulative value reaching tens of billions of RMB. These transactions span various sub-sectors, including new drug development, medical devices, diagnostics, consumer healthcare, healthcare services, smart healthcare, and health insurance.

In the China Financial Advisory Firm Rankings hosted by Qiming Technology, a financial big data institution, Life Capital was selected as one of the Top 3 financial advisory firms in the Chinese healthcare sector. At VCBeat’s Future Healthcare 100 event, Life Capital was named “Healthcare Financial Advisory Firm of the Year.”